Classic view of this page
HopeSeq Solid Tumors Comprehensive Panel
Clinical Genetic Test
Help
offered by
Clinical Molecular Genomics & Cytogenomics Laboratory
View lab's test page
LinkOut
GTR Test Accession: Help GTR000552196.1
CAP
Last updated in GTR: 2025-01-28
View version history
Last annual review date for the lab: 2019-10-16 Past due LinkOut
At a Glance
Test purpose: Help
Diagnosis; Prognostic; Therapeutic management
Conditions (2): Help
Hereditary cancer; Solid tumor
Genes (606): Help
ABL1 (9q34.12); ABL2 (1q25.2); ABRAXAS1 (4q21.23); ACVR1 (2q24.1); ACVR1B (12q13.13) more...
Methods (1): Help
Molecular Genetics - Sequence analysis of select exons: Next-Generation (NGS)/Massively parallel sequencing (MPS)
Target population: Help
Not provided
Clinical validity: Help
This assay has been clinically used for diagnosis, prognosis, and …
Clinical utility: Help
Not provided
Ordering Information
Offered by: Help
Clinical Molecular Genomics & Cytogenomics Laboratory
View lab's website
View lab's test page
Specimen Source: Help
Test Order Code: Help
HopeSeq
Lab contact: Help
Michelle Afkhami, MD, ABPath, FCAP, CLIA License Holder
[email protected]
844-313-5227
Informed consent required: Help
Decline to answer
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
How to Order, Contact policy, Test strategy, Test development
Conditions Help
Total conditions: 2
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 606
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 1
Method Category Help
Test method Help
Instrument *
Sequence analysis of select exons
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose: Help
Diagnosis; Prognostic; Therapeutic management
Clinical validity: Help
This assay has been clinically used for diagnosis, prognosis, and target therapy across all solid tumor sub-type for more than 3000 specimens per year.
View citations (1)
  • De Andrade JP, Wong P, O'Leary MP, Parekh V, Amini A, Schoellhammer HF, Margolin KA, Afkhami M, Melstrom LG. Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling. Ann Surg Oncol. 2020;27(13):5240-5247. doi:10.1245/s10434-020-09112-2. Epub 2020 Sep 09. PMID: 32909128.
Recommended fields not provided:
Clinical utility, Target population, What is the protocol for interpreting a variation as a VUS?, Is research allowed on the sample after clinical testing is complete?, Sample negative report, Sample positive report
Technical Information
Test Comments: Help
See https://www.cityofhope.org/clinical-molecular-diagnostic-laboratory/cmdl-test-list/hopeseq-solid-tumor-complete for assay information on genes, regarding exon mutation analysis, Copy Number Variation (CNV) analysis, and fusion analysis
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
Technical accuracy greater than 97%
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
Yes

Method used for proficiency testing: Help
Formal PT program

PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
Recommended fields not provided:
Test Confirmation, Assay limitations, Description of internal test validation method, Citations for Analytical validity, Description of PT method, Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review: Help
Category: FDA exercises enforcement discretion
Additional Information
Consumer resources:

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.